- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Jonathan Sweeting on Aybintio's European Approval
We sat down with Jonathan Sweeting, head of Samsung Bioepis’ European business, to discuss the steps leading up to the European approval of Aybintio and what the current bevacizumab market in Europe looks like.
In August, Samsung Bioepis, a biopharmaceutical manufacturer based in the Republic of Korea, received European Commission (EC) marketing authorization for its bevacizumab biosimilar, Aybintio.
The EC approved Aybintio for all indications of the reference product, Avastin, including colorectal, breast, and lung cancer. Although Aybintio will increase price competition in Europe, how the individual biosimilar will fare against its already established competitors remains to be seen.
We sat down with Jonathan Sweeting, head of Samsung Bioepis’ European business, to discuss the steps leading up to the approval of Aybintio and what the current bevacizumab market in Europe looks like.
To learn more about the EC's approval of Aybintio, click here.
To learn more about Samsung Bioepis, click here.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
